Does H. pylori eradication therapy benefit patients with hepatic encephalopathy?: Systematic review

Journal of Clinical Gastroenterology

Volumn 48, Issue 6, 2014, Pages 491-499

  Schulz, Christian ^a   Schütte, Kerstin ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Helicobacter pylori; hepatic encephalopathy; hyperammonemia; minimal hepatic encephalopathy

Indexed keywords

ACETOHYDROXAMIC ACID; AMINO ACID; AMMONIA; AMOXICILLIN; BISMUTH; CLARITHROMYCIN; DISACCHARIDE; GLUTAMINASE; KANAMYCIN; LACTULOSE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PAROMOMYCIN; TINIDAZOLE; UREASE INHIBITOR; UREASE;

ALCOHOL LIVER DISEASE; AMMONIA BLOOD LEVEL; AMMONIA FORMATION; ANTIBIOTIC THERAPY; ASCITES; CHILD PUGH SCORE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COLON FLORA; CRITICAL FLICKER FUSION; DATA BASE; ERADICATION THERAPY; HELICOBACTER INFECTION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; INFECTION RATE; LIVER CIRRHOSIS; MEDLINE; METHODOLOGY; NUTRITIONAL PARAMETERS; OBSERVATIONAL STUDY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CALORIE MALNUTRITION; REVIEW; RISK FACTOR; STOMACH JUICE; SYSTEMATIC REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; COMPLICATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTESTINE; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; INTESTINES; LIVER CIRRHOSIS; UREASE;

EID: 84902548234     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000108     Document Type: Review

References (61)

1. Patel D, McPhail MJW, Cobbold JFL, et al. Hepatic encephalopathy. Br J Hosp Med (Lond). 2012;73:79-85.
2. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hep-atology. 2002;35:716-721.
3. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23:398-406.
4. Bianchi G, Giovagnoli M, Sasdelli AS, et al. Hepatic encephalopathy and health-related quality of life. Clin Liver Dis. 2012;16:159-170.
5. Poordad FF. Review article: the burden of hepatic encephal-opathy. Aliment Pharmacol Ther. 2007;25(suppl 1):3-9.
6. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31: 537-547.
7. Groeneweg M, Quero JC, Bruijn Ide, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45-49.
8. Albrecht J. Astrocytes in ammonia neurotoxicity: a target, a mediator and a shield. In: Aschner M, Costa LG, eds. The Role of Glia in Neurotoxicity. Boca Raton, FL: CRC Press; 2005:329-342.
9. Lavoie J, Giguere JF, Layrargues GP, et al. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem. 1987;49:692-697.
10. McConnell JR, Antonson DL, Ong CS, et al. Proton spectroscopy of brain glutamine in acute liver failure. Hepatology. 1995;22:69-74.
11. Rama Rao KV, Reddy PVB, Tong X, et al. Brain edema in acute liver failure: inhibition by L-histidine. Am J Pathol. 2010;176:1400-1408.
12. Norenberg MD, Bender AS. Astrocyte swelling in liver failure: role of glutamine and benzodiazepines. Acta Neurochir Suppl (Wien). 1994;60:24-27.
13. Wright G, Soper R, Brooks HF, et al. Role of aquaporin-4 in the development of brain oedema in liver failure. J Hepatol. 2010;53:91-97.
14. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324:1852-1857.
15. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, et al. Role of astrocytes in brain function and disease. Toxicol Pathol. 2011;39:115-123.
16. Gorg B, Qvartskhava N, Bidmon H, et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology. 2010;52:256-265.
17. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57:1156-1165.
18. Murthy CR, Rama Rao KV, Bai G, et al. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. J Neurosci Res. 2001;66:282-288.
19. Bruck J, Gorg B, Bidmon H, et al. Locomotor impairment and cerebrocortical oxidative stress in portal vein ligated rats in vivo. J Hepatol. 2011;54:251-257.
20. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011;140:478-487, e1.
21. Foster KJ, Lin S, Turck CJ. Current and emerging strategies for treating hepatic encephalopathy. Crit Care Nurs Clin North Am. 2010;22:341-350.
22. Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28:307-312.
23. Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28:313-320.
24. Sidhu SS, Goyal O, Mishra BP, et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011;106:307-316.
25. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
26. Conn HO. Studies of the source and significance of blood ammonia. IV. Early ammonia peaks after ingestion of ammonium salts. Yale J Biol Med. 1972;45:543-549.
27. Fitzgerald O, Murphy P. Role of gastric urease. Nature. 1948;162:896.
28. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336-341.
29. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380-382.
30. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401-406.
31. Fitzgerald O. Urease in the gastric mucosa and its increase after a meat diet, soya bean flour diet or urogastrone infections. Nature. 1946;158:305.
32. Aoyagi T, Engstrom GW, Evans WB, et al. Gastrointestinal urease in man. I. Activity of mucosal urease. Gut. 1966;7: 631-635.
33. Evans WB, Aoyagi T, Summerskill WH. Gastrointestinal urease in man. II. Urea hydrolysis and ammonia absorption in upper and lower gut lumen and the effect of neomycin. Gut. 1966;7:635-639.
34. Ito S, Kohly Y, Kato T, et al. Significance of ammonia produced by Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994;6:167-174.
35. Suto H, Azuma T, Ito S, et al. Helicobacter pylori infection induces hyperammonaemia in Mongolian gerbils with liver cirrhosis. Gut. 2001;48:605-608.
36. Gundling F, Zelihic E, Seidl H, et al. How to diagnose hepatic encephalopathy in the emergency department. Ann Hepatol. 2013;12:108-114.
37. Gubbins GP, Moritz TE, Marsano LS, et al. Helicobacter pylori is a risk factor for hepatic encephalopathy in acute alcoholic hepatitis: the ammonia hypothesis revisited. The Veterans Administration Cooperative Study Group No. 275. Am J Gastroenterol. 1993;88:1906-1910.
38. Sethar GH, Ahmed R, Zuberi BF, et al. Frequency of Helicobacter pylori antibodies in porto-systemic encephalop-athy. J Coll Physicians Surg Pak. 2004;14:530-533.
39. Huber M, Rossle M, Siegerstetter V, et al. Helicobacter pylori infection does not correlate with plasma ammonia concentration and hepatic encephalopathy in patients with cirrhosis. Hepatogastroenterology. 2001;48:541-544.
40. Rekha C, Phanidhar S, Sagar AV, et al. Role of Helicobacter pylori and hyperammonemia in subclinical hepatic encephal-opathy in cirrhosis of liver. Indian J Clin Biochem. 2007; 22:136-139.
41. Chakrabarti P, Zullo A, Hassan C, et al. Helicobacter pylori, gastric juice, and arterial ammonia levels in patients with cirrhosis. J Clin Gastroenterol. 2002;34:578-581.
42. Kini D, Aggarwal R, Saraswat VA, et al. Role of Helicobacter pylori infection in hyperammonemia and subclinical hepatic encephalopathy in cirrhosis of liver. Indian J Gastroenterol. 2001;20:237-240.
43. Calvet X, Nogueras C, Roque M, et al. Helicobacter pylori is not a risk factor for hepatic encephalopathy. Dig Liver Dis. 2001;33:414-419.
44. Romero-Gomez M, Grande L, Camacho I, et al. Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalop-athy. J Hepatol. 2002;37:781-787.
45. Si J, Cao Q, Gao M, et al. Changes in serum ammonia concentration in cirrhotic patients with Helicobacter pylori infection. Chin Med J. 2000;113:1080-1081.
46. Zullo A, Rinaldi V, Hassan C, et al. Helicobacter pylori and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Ital J Gastroenterol Hepatol. 1998; 30:405-409.
47. Ito S, Miyaji H, Azuma T, et al. Hyperammonaemia and Helicobacter pylori. Lancet. 1995;346:124-125.
48. Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol. 1998;93:726-731.
49. Miyaji H, Ito S, Azuma T, et al. Effects of Helicobacter pylori eradication therapy on hyperammonaemia in patients with liver cirrhosis. Gut. 1997;40:726-730.
50. Abdel-Hady H, Zaki A, Badra G, et al. Helicobacter pylori infection in hepatic encephalopathy: relationship to plasma endotoxins and blood ammonia. Hepatol Res. 2007;37: 1026-1033.
51. Chen S, Wang L, Zhu Q, et al. Effect of H. pylori infection and its eradication on hyperammo-nemia and hepatic encephalo-pathy in cirrhotic patients. World J Gastroenterol. 2008;14: 1914-1918.
52. Agrawal A, Gupta A, Chandra M, et al. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. Indian J Gastro-enterol. 2011;30:29-32.
53. Demirturk L, Yazgan Y, zci O, et al. The effect of Helicobacter pylori eradication on gastric juice and blood ammonia concentrations and on visual evoked potentials in cirrhotics. Helicobacter. 2001;6:325-330.
54. Nandakumar R, Naik AS, Pandit B, et al. Effect of Helicobacter pylori eradication on serum ammonia levels in patients with chronic liver disease. Indian J Gastroenterol. 2003;22:221-223.
55. Shavakhi A, Shariatifar B, Chuloo SA, et al. Effect of Helicobacter pylori eradication on hepatic encephalopathy. Hepatitis Monthly. 2008;8:121-124.
56. Miquel J, Barcena R, Boixeda D, et al. Role of Helicobacter pylori infection and its eradication in patients with subclinical hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2001;13:1067-1072.
57. Scotiniotis IA, Lucey MR, Metz DC. Helicobacter pylori infection is not associated with subclinical hepatic encephal-opathy in stable cirrhotic patients. Dig Dis Sci. 2001;46: 2744-2751.
58. Quero JC, Hartmann IJ, de Rooij F, et al. Hyperammonaemia and Helicobacter pylori. Lancet. 1995;346:713-714.
59. Vasconez C, Elizalde JI, Llach J, et al. Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalop-athy: effects of eradication. J Hepatol. 1999;30:260-264.
60. Zullo A, Rinaldi V, Meddi P, et al. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Am J Gastroenterol. 1999;94:2214-2218.
61. Guyatt GH, Oxman AD, Schunemann HJ. GRADE guide-lines-an introduction to the 10th-13th articles in the series. J Clin Epidemiol. 2013;66:121-123.